Patent ID: 8524975

Claim:
A method of predicting a behavior of a single drug or a plurality of drugs in a human, as part of a drug screening or evaluation process, comprising: administering the single drug or the plurality of drugs to a transgenic mouse comprising in its genome a homozygous disruption of an endogenous mouse cytochrome P450 (CYP) gene and a stably integrated nucleotide sequence that encodes a human CYP polypeptide operably linked to a promoter, wherein the expression of an endogenous CYP polypeptide from the endogenous CYP gene is abrogated, and wherein the human CYP polypeptide is a homolog of said mouse CYP polypeptide and is other than the intended target of the single drug or plurality of drugs, and wherein expression of the nucleotide sequence that encodes the human CYP polypeptide provides a mouse that predicts behavior of a drug in a human, and conducting an analytical test to determine the behavior of the single drug or the plurality of drugs in the transgenic mouse, the results of which have a higher correlation to the behavior of the drug in the human than the results obtained from a wild type mouse; wherein the human CYP polypeptide is from a CYP family selected from the group consisting of: CYP 1, CYP 2, and CYP 3.